State Street(R) SPDR(R) S&P(R) Biotech ETF is a ETF series of SPDR SERIES TRUST (series S000010018). Net assets $7.4B as of 2026-03-31. Index fund.
Showing 15 of 158 holdings by value.
| Holding | Ticker | Value | % of fund |
|---|---|---|---|
| State Street Global Advisors | — | $595.5M | 800.95% |
| Apellis Pharmaceuticals Inc | — | $136.4M | 183.47% |
| Alkermes PLC | — | $107.9M | 145.10% |
| Madrigal Pharmaceuticals Inc | — | $102.8M | 138.29% |
| TG Therapeutics Inc | — | $100.3M | 134.96% |
| Insmed Inc | — | $99.4M | 133.69% |
| Scholar Rock Holding Corp | — | $96.5M | 129.73% |
| Apogee Therapeutics Inc | — | $95.5M | 128.43% |
| Protagonist Therapeutics Inc | — | $92.5M | 124.49% |
| Summit Therapeutics Inc | — | $92.3M | 124.11% |
| United Therapeutics Corp | — | $92.2M | 124.05% |
| Praxis Precision Medicines Inc | — | $91.9M | 123.62% |
| Arrowhead Pharmaceuticals Inc | — | $91.4M | 122.98% |
| Cogent Biosciences Inc | — | $90.4M | 121.57% |
| Bridgebio Pharma Inc | — | $88.1M | 118.55% |
| Report date | Net assets |
|---|---|
| 2026-03-31 | $7.4B |
| 2025-12-31 | $7.8B |
| 2025-09-30 | $5.7B |
| 2025-06-30 | $4.8B |
| 2025-03-31 | $5.1B |
| 2024-12-31 | $6.4B |
| 2024-09-30 | $7.7B |
| 2024-06-30 | $7.1B |